PMID- 35513898
OWN - NLM
STAT- MEDLINE
DCOM- 20220630
LR  - 20230912
IS  - 1536-481X (Electronic)
IS  - 1057-0829 (Print)
IS  - 1057-0829 (Linking)
VI  - 31
IP  - 7
DP  - 2022 Jul 1
TI  - Association Between Serum Vitamin D Level and Rates of Structural and Functional 
      Glaucomatous Progression.
PG  - 614-621
LID - 10.1097/IJG.0000000000002046 [doi]
AB  - PRCIS: In a retrospective cohort study, serum vitamin D levels were not 
      associated with rates of structural or functional loss in glaucoma patients, 
      suggesting that low vitamin D level is not a risk factor for progression. 
      PURPOSE: To investigate the association between serum vitamin D level and rates 
      of functional and structural glaucomatous loss over time. METHODS: This study 
      included 826 eyes of 536 glaucoma or suspect patients with an average follow-up 
      of 4.8+/-1.9 years. All patients had at least 1 serum vitamin D measurement, and 
      all eyes had at least 2 reliable standard automated perimetry (SAP) tests and 2 
      spectral-domain optical coherence tomography (SD OCT) tests with a minimum 
      follow-up of 6 months. Multivariable linear mixed-effects models were used to 
      estimate the association of vitamin D level with rates of change in SAP mean 
      deviation (MD) and OCT retinal nerve fiber layer (RNFL) thickness over time while 
      adjusting for potential confounding factors. RESULTS: Patients had an average of 
      3.4+/-1.7 SAP tests, 4.8+/-1.9 SD OCT tests, and 2.3+/-1.9 vitamin D measurements. The 
      average serum vitamin D level was 33.9+/-13.2 ng/mL. Mean rates of MD and RNFL 
      change were -0.03+/-0.08 dB/y and -0.68+/-0.64 microm/y, respectively. After controlling 
      for confounding factors, there was no statistically significant association 
      between mean vitamin D level and rates of MD (beta=0.038, 95% CI: -0.006, 0.082, P 
      =0.09) or RNFL loss over time (beta=-0.018, 95% CI: -0.092, 0.055, P =0.62). 
      CONCLUSIONS: We did not find a significant association between vitamin D level 
      and rates of visual field or RNFL loss over time in individuals with glaucoma and 
      glaucoma suspect patients.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Lee, Terry
AU  - Lee T
AD  - Vision, Imaging and Performance Laboratory (VIP), Duke Eye Center and Department 
      of Ophthalmology, Duke University.
FAU - Jammal, Alessandro A
AU  - Jammal AA
AD  - Vision, Imaging and Performance Laboratory (VIP), Duke Eye Center and Department 
      of Ophthalmology, Duke University.
FAU - Medeiros, Felipe A
AU  - Medeiros FA
AD  - Vision, Imaging and Performance Laboratory (VIP), Duke Eye Center and Department 
      of Ophthalmology, Duke University.
AD  - Department of Electrical and Computer Engineering, Pratt School of Engineering, 
      Duke University, Durham, NC.
LA  - eng
GR  - R01 EY029885/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20220506
PL  - United States
TA  - J Glaucoma
JT  - Journal of glaucoma
JID - 9300903
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Disease Progression
MH  - *Glaucoma/diagnosis
MH  - Humans
MH  - Intraocular Pressure
MH  - *Nerve Fibers
MH  - Retinal Ganglion Cells
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence/methods
MH  - Visual Field Tests/methods
MH  - Vitamin D
PMC - PMC10287058
MID - NIHMS1803112
COIS- Disclosure: F.A.M.: Aeri Pharmaceuticals (C); Allergan (C, F), Annexon (C); 
      Biogen (C); Carl Zeiss Meditec (C, F), Galimedix (C); Google Inc. (F); Heidelberg 
      Engineering (F), IDx (C); nGoggle Inc. (P), Novartis (F); Stealth Biotherapeutics 
      (C); Reichert (C, F). The remaining authors declare no conflict of interest.
EDAT- 2022/05/07 06:00
MHDA- 2022/07/01 06:00
PMCR- 2023/07/01
CRDT- 2022/05/06 00:03
PHST- 2021/09/30 00:00 [received]
PHST- 2022/04/28 00:00 [accepted]
PHST- 2022/05/07 06:00 [pubmed]
PHST- 2022/07/01 06:00 [medline]
PHST- 2022/05/06 00:03 [entrez]
PHST- 2023/07/01 00:00 [pmc-release]
AID - 00061198-202207000-00018 [pii]
AID - 10.1097/IJG.0000000000002046 [doi]
PST - ppublish
SO  - J Glaucoma. 2022 Jul 1;31(7):614-621. doi: 10.1097/IJG.0000000000002046. Epub 
      2022 May 6.